High-dose statin therapy: Benefits and safety in aggressive lipid lowering

Journal of Family Practice

Volumn 57, Issue 5, 2008, Pages

  Toth, Peter P ^a,b   Davidson, Michael H ^c,d  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Sterling Rock Falls Clinic ^*  (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DIGITALIS; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; BRAIN HEMORRHAGE; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT RESPONSE;

EID: 43449125613     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Van AT, Yan RT, Tan M, et al, for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2487.
3. Grundy SM, Cleeman JI, Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-239.
4. Pedersen TR, Faergeman O, Kastelein JJ, et al, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
5. LaRosa JC, Grundy SM, Waters DD, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
6. Camion CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Tlierapy-Thromholysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
7. VA/DoD Clinical Practice Guidelines. Appendix F: Pharmacologic Therapy Summary of Supporting Studies. http://www.oqp.med.va.gov/cpg/dl/lip_cpg/content/ appendices/appn_f.htm. Accessed April 8, 2008.
8. Wiviott SD, Cannon CP, Morrow DA, et al, for the PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving verv low low-density lipoprotein with intensive statin therapy: a PROVEIT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-1416.
9. Deedwania P, Barter P, Carmena R, et al, for the Treating to New Targets (TNT) Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919-928.
10. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49:1753-1762.
11. Olsson AG, Schwartz GG, Szarek M, et al. Effects of high-dose atorvastatin in patients ≥65 years of age with acute coronary syndrome (from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering [MIRACL] study). Am J Cardiol. 2007;99:632-635.
12. Wenger NK, Lewis SJ, Harrington DM, et al, for the Treating to New Targets (TNT) Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1-9.
13. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
15. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-583.
16. Toth PP. Intensive LDL-C lowering: Which patients benefit? Family Practice Recertification. http://www.fpronline.com/ArticlePrinterFriendly.cfm? ID=383. Accessed Dec 20, 2007.
17. Farsang C, Athyros V, Gaw A, for the ACTFAST-2 Investigators and Steering Committee Members. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Curr Med Res Opin. 2007;23:1945-1956.
18. Jones PH, McKenney JM, Karalis DG, et al, for the NASDAC Investigators. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005;149:e1-e8.
19. Koren MJ, Hunninghake DB, for the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in Iipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-1779.
20. LaRosa JC, Grundy SM, Kastelein JJ, et al, for the Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol. 2007;100:747-752.
21. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97:61-67.
22. Waters DD. Safety of high-dose atorvaslatin therapy. Am J Cardiol. 2005;96(snppl):69F-75F.
23. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. Insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409-418.
24. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97(suppl):44C-51C.
25. Zocor [prescribing information]. http://www.zocor.com/simvastatin/zocor/ hcp/product_information/pi/index.jsp, Whitehouse Station, NJ: Merck & Co., Inc. Accessed Feb 28, 2008.
26. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
27. Baigent C, Keech A, Kearney PA, et al, for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;306:1267-1278.
28. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
29. Stern R, Abel R, Gibson GL, et al. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37:1062-1064.
30. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother. 2007;41:1292-1295.
31. Holtzman CW, Wiggins BS, Spinier SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006;26:1601-1067.
32. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol. 2005;8:95-97.
33. Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fihrate therapy. Am J Cardiol. 2007;99(suppl):3C-18C.
34. Saw J, Brennan DM, Steinhubl SR, et al, for the CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007;50:291-295.
35. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol. 2007;99:379-381.
36. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-loweriug drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581.
37. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23:2009-2026.
38. American College of Cardiology. ENHANCE trial results: Statins remain first line. http://acc.org/enhance_statement.htm. Accessed April 4, 2008.